SCOTTISH biomaterials manufacturer Angel Biotechnology has secured a deal to assist ReNeuron with its stem cell work.

Angel, which has sites in both Edinburgh and Glasgow, told investors the contract is scheduled for completion in the current financial year.

ReNeuron has been pursuing trials of stem cell therapy for stroke patients at Glasgow's Southern General Hospital.

Angel's spokesman was unable to confirm whether the contract related to the Glasgow study.

Nicholas Smith, chairman of Angel said: "Angel continues to build on its track record of providing its expertise and services to ReNeuron Group."

ReNeuron chief executive Michael Hunt said: "This contract will ensure the provision of further drug substance material required to service our on-going therapeutic programmes."